Skip to content

Parvovirus B19 Infection in Pregnancy: Clinical Manifestations and Fetus/Newborn Outcome

Parvovirus B19 Infection in Pregnancy: Clinical Manifestations and Fetus/Newborn Outcome

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07338279
Acronym
ParvoPre
Enrollment
150
Registered
2026-01-13
Start date
2025-03-06
Completion date
2027-12-31
Last updated
2026-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parvovirus B19 Infection, Pregnancy

Brief summary

The goal of this observational study is to define the rate of intrauterine parvovirus B19 infection and fetal/newborn complications after parvovirus B19 infection of pregnant women. Secondary objectives are risk factors, pregnancy outcomes, long-term sequelae and efficacy of the management interventions.

Interventions

OTHERCollection of clinical data.

Observational study

Sponsors

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
CollaboratorOTHER
ASST Fatebenefratelli Sacco
CollaboratorOTHER
Fondazione IRCCS San Gerardo dei Tintori
CollaboratorOTHER
Asst Degli Spedali Civili Di Brescia
CollaboratorOTHER
Fondazione IRCCS Policlinico San Matteo di Pavia
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
OTHER

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Pregnant women \>18 years with parvovirus B19 infection and their neonates.

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frame
Percentage of fetuses/newborns with intrauterine B19V infection.From diagnosis of parvovirus B19 infection in pregnancy to 24/48 hours of life of the newborn.
Percentage of fetuses/newborns with complications due to B19V intrauterine infection.From diagnosis of parvovirus B19 infection in pregnancy to 24/48 hours of life of the newborn.

Secondary

MeasureTime frameDescription
Percentage of fetuses receiving intrauterine transfusion.From diagnosis of parvovirus B19 infection in pregnancy to delivery.
Percentage of women with symptomatic B19V infection.At diagnosis of parvovirus B19 infection in pregnancy
Percentage of infants with neurologic abnormalities.From birth to 2 years of life.
Percentage of newborns with B19V disease.From diagnosis of parvovirus B19 infection in pregnancy to 20/30 days of life of the newborn.The following signs/symptoms will be considered: anemia, paleness, petechiae, purpura, icterus, hepato-splenomegaly, ascites, hydrops, pleural effusion, pericardial effusion, neurologic abnormalities.
Percentage of fetuses with B19V disease.From diagnosis of parvovirus B19 infection in pregnancy to delivery.The following findings will be considered: anemia, hydrops, ascites, pericardial effusion, pleural effusion, subcutaneus oedema, cardiomegaly, placental thickening, cerebral abnormalities, growth retardation.

Countries

Italy

Contacts

Primary ContactDaniele Lilleri
d.lilleri@smatteo.pv.it+39 0382 502420

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026